health:economy: For 20 years now, the pioneering Austrian company TissueGnostics GmbH has been working
successfully in the field of precision medicine with a variety of partners, including oncology centres around the world.
On average, all of us have an increasing life expectancy, and there is a global trend towards more prosperity. At the same time, the number of patients who have serious illnesses, such as cancer, is increasing significantly in the world’s population.
Overall, there are too few resources in the form of doctors, institutions and therapies for the efficient treatment of these diseases using traditional means. One of the biggest challenges of our time is to use research, continuously optimised diagnostic methods and therapies to improve every patient’s prognosis, regardless of their socioeconomic status.
The ongoing digitisation of medicine has facilitated the collection and analysis of patient data to an extent that was never possible before. As the analysis of a variety of biomolecular measurement data becomes more and more accurate, it is
possible to make more precise diagnoses; this is why we often talk about technologydriven medicine or precision medicine in this context. Dedicated scientists develop new techniques, mostly quantitative in nature, and they become milestones in the diagnosis and personalised treatment of cancer and other diseases.
An outstanding example is the Viennese company TissueGnostics GmbH, founded in 2003, which is now active globally and has offices in the EU, USA, Australia and Asia, particular in China.
"Research and development in the field of precision medicine definitely pays off in every regard", explain TissueGnostics Founder and CEO Rupert Ecker, Asia / Pacific Managing Director Wu Hai (in Mandarin with Subtitles in English) and Scientist Jyotsna Batra of the Translational Research Institute of the Queensland University of Technology, Australia.
Since this medianet.tv production will be distributed worldwide, it was realized in English.
